FDA authorizes AstraZeneca's COVID-19 antibody cocktail

The US Food and Drug Administration (FDA) on Wednesday authorized AstraZeneca's antibody cocktail to prevent COVID-19 infections in individuals who have weak immune systems or a history of severe side effects from coronavirus vaccines, Reuters reports.

While vaccines rely on an intact immune system to develop targeted antibodies and infection-fighting cells, AstraZeneca's therapy Evusheld contains lab-made antibodies designed to linger in the body for months to contain the virus in case of an infection.